Lifestance Health Group Inc (LFST)
Official siteHEALTHCARE • MEDICAL CARE FACILITIES • NASDAQ
Market Cap: $5.35B
Last updated: Nov 17, 2026 at 11:06 AM ET
Lifestance Health Group Inc (LFST) Stock Forecast
Analysts expect Lifestance Health Group (LFST) to earn $0.40 per share in the fiscal year ending Dec 31, 2026, on revenue of $1.75B. Of 11 analysts, 9 rate the stock Buy or Strong Buy, 2 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 3 estimates for the fiscal year ending Dec 31, 2026 were revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 11 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 82% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 2 | 18.2% |
| Buy | 7 | 63.6% |
| Hold | 2 | 18.2% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 11
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 12.5% and revenue estimates rise 13.1%.
- Fiscal year ending Dec 31, 2026
- $0.40
- EPS consensus, revenue $1.75B
- Fiscal year ending Dec 31, 2027
- $0.45
- EPS consensus, revenue $1.98B
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.40 | $0.40 to $0.42 | 4 | $1.75B | $1.71B to $1.76B | 10 |
| Dec 31, 2027 | $0.45 | $0.38 to $0.51 | 5 | $1.98B | $1.94B to $2.01B | 10 |
Quarterly Estimates
The EPS consensus rises from $0.04 for the quarter ending Dec 31, 2026 to $0.10 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.04 | $0.02 to $0.06 | 13 | $462.39M | $433.95M to $483.64M | 11 |
| Mar 31, 2027 | $0.10 | $0.09 to $0.11 | 2 | $462.50M | $457.25M to $466.61M | 3 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 6 upward and 0 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 3 | 0 |
| Fiscal year ending Dec 31, 2027 | 1 | 0 |
| Quarter ending Mar 31, 2027 | 2 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has fallen 2.4% from $0.41.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $0.40 | $0.36 | $0.36 | $0.40 | $0.41 | -2.6% |
| Fiscal year ending Dec 31, 2027 | $0.45 | $0.43 | $0.43 | $0.53 | $0.52 | -14.1% |
| Quarter ending Mar 31, 2027 | $0.10 | $0.10 | $0.10 | $0.10 | $0.10 | -0.5% |
Frequently Asked Questions About LFST
What is the LFST stock forecast?
Consensus analyst estimates put Lifestance Health Group's EPS at $0.40 for the fiscal year ending Dec 31, 2026, on revenue of $1.75B. The consensus rating from 11 analysts is Buy.
How do analysts rate LFST stock?
Of 11 analysts covering Lifestance Health Group, 2 rate it Strong Buy, 7 Buy, 2 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from LFST next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $0.40, with estimates from $0.40 to $0.42 from 4 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $0.45, with estimates from $0.38 to $0.51 from 5 analysts.
What revenue do analysts expect from Lifestance Health Group next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $1.75B, with estimates from $1.71B to $1.76B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $1.98B, with estimates from $1.94B to $2.01B.
How many analysts cover LFST?
11 analysts rate Lifestance Health Group stock, and 4 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
LFST pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors